PEDRO PIEDRA to Palivizumab
This is a "connection" page, showing publications PEDRO PIEDRA has written about Palivizumab.
Connection Strength
0.950
-
Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. J Infect Dis. 2018 03 28; 217(8):1247-1256.
Score: 0.578
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
Score: 0.150
-
Eligibility for palivizumab prophylaxis in a cohort of children with severe bronchiolitis. Pediatr Int. 2015 Oct; 57(5):1031-4.
Score: 0.122
-
The Human Nose Organoid Respiratory Virus Model: an Ex Vivo Human Challenge Model To Study Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pathogenesis and Evaluate Therapeutics. mBio. 2021 02 22; 13(1):e0351121.
Score: 0.044
-
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
Score: 0.030
-
Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
Score: 0.025